<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01889355</url>
  </required_header>
  <id_info>
    <org_study_id>AGAFPGM01</org_study_id>
    <nct_id>NCT01889355</nct_id>
  </id_info>
  <brief_title>User Study for Enhanced Meter Feature</brief_title>
  <official_title>User Study for the Evaluation of an Enhanced Meter Feature Using an AgaMatrix BGMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AgaMatrix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AgaMatrix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This enhanced meter feature raises awareness among patients by providing additional
      information regarding their glycemic control in between Healthcare Professional visits. This
      information may facilitate increased dialogue between patient and Healthcare Professional and
      can remind patients of the importance of glycemic control.

      This study will evaluate a user's ability to use the enhanced meter feature.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enhanced Meter Feature Usability</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary objective of this study is to evaluate that the intended users are able to obtain accurate blood glucose measurements when operating the blood glucose monitoring system, given only the training materials routinely provided with the system (ISO 15197:2013 8.1).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Enhanced meter feature usability</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Home diabetes monitoring by patient using provided blood glucose monitoring system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AgaMatrix Blood Glucose Monitor</intervention_name>
    <arm_group_label>Enhanced meter feature usability</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        IC 1. Age of subject is 18 years or older

        IC 2. Type I or type II diabetes inclusive of the following populations:

          1. Mixed insulin therapies

          2. Basal insulin therapies

          3. Bolus insulin therapies

          4. CSII therapies

          5. MDI therapies

          6. Non-insulin diabetic treatments (oral and injectable)

          7. Life style (exercise and diet) diabetes management IC 3. Able to speak and read
             English proficiently

        Exclusion criteria EC 1. Pregnant EC 2. Hct &lt;20 or &gt;60 EC 3. Work for BGM competitor
        company (including, but not limited to Lifescan, Roche, Abbott) EC 4. Homeless EC 5.
        Incarcerated EC 6. Institutionalized EC 7. Employees or students of the Research Site,
        including the Principal Investigator, directly involved in the conduct of the protocol.

        EC 8. Has any condition that the Principal Investigator believes may interfere in the
        subject's participation in the study.

        EC 9. Previous experience using the MyStar Extra BGMS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <results_first_submitted>July 10, 2018</results_first_submitted>
  <results_first_submitted_qc>July 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2018</results_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>glucose</keyword>
  <keyword>glucometer</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Procedure</title>
          <description>5.5 Evaluation Procedure The evaluation shall be performed in the following sequence and be supervised by one or more healthcare providers trained in the use of the device under evaluation (ISO 15197:2013 8.1).
Briefly describe to the subject that the goal of this study is to obtain a blood glucose reading, describe the study procedures, and obtain written informed consent ensuring all questions are answered.
For each consenting study subject, assign a sequential User ID number and obtain inclusion criteria, exclusion criteria, and user demographics.
Perform a urine pregnancy test for women of childbearing potential if pregnancy status unknown.
Locate subjects to a private area where they are not able to see others performing the test.
The trained technician will put on a new pair of gloves.
Provide the subject with an AgaMatrix meter, test strips, the system kit lancing device and lancets. Prior to performing self-testing, each study subject shall</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Demographics</title>
          <description>Age group ranged from ages 18-86, Male and female with both Type 1 and Type 2 diabetics. Race was both white, black/African American and Hispanic who are able to read and understand English per the subject consent form.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Enhanced Meter Feature Usability</title>
        <description>The primary objective of this study is to evaluate that the intended users are able to obtain accurate blood glucose measurements when operating the blood glucose monitoring system, given only the training materials routinely provided with the system (ISO 15197:2013 8.1).</description>
        <time_frame>4 weeks</time_frame>
        <population>All diabetic subjects who volunteer for the study and qualify in accordance with the study inclusion and exclusion criteria, the user requirements established by the manufacturer for the blood-glucose system, and applicable regulatory requirements, shall be eligible to participate in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Subject Population, Inclusion and Exclusion</title>
            <description>This clinical study will consist of at least 50 evaluable subjects who meet all inclusion/exclusion criteria.
Subjects shall be selected using the consecutive sampling method. All diabetic subjects who volunteer for the study and qualify in accordance with the study inclusion and exclusion criteria, the user requirements established by the manufacturer for the blood-glucose system (e.g. packed cell volume within the systemâ€™s specified limits), and applicable regulatory requirements (e.g. written informed consent), shall be eligible to participate in the study (ISO 15197:2013 8.3).
3.2 Inclusion Criteria
Potential participants may be enrolled in the study if they satisfy the following inclusion criteria:
IC 1. Age of subject is 18 years or older IC 2. Has been diagnosed with Type1 or Type 2 diabetes IC 3. Able to speak and read English proficiently IC 4. Must be physically able to self-test
3.3 Exclusion Criteria Potential subjects who display any o</description>
          </group>
        </group_list>
        <measure>
          <title>Enhanced Meter Feature Usability</title>
          <description>The primary objective of this study is to evaluate that the intended users are able to obtain accurate blood glucose measurements when operating the blood glucose monitoring system, given only the training materials routinely provided with the system (ISO 15197:2013 8.1).</description>
          <population>All diabetic subjects who volunteer for the study and qualify in accordance with the study inclusion and exclusion criteria, the user requirements established by the manufacturer for the blood-glucose system, and applicable regulatory requirements, shall be eligible to participate in the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adverse and Serious Events</title>
          <description>No adverse or serious events occurred during this study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Clinical Research Technician</name_or_title>
      <organization>AgaMatrix, Inc</organization>
      <phone>603-328-6035</phone>
      <email>krocha@agamatrix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

